David Raskin
Hematology & Oncology · Sunrise, FLNPI 1023082112
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,041 of the $5,660 with a category attached, or 89.1%. It is spread thinly across 32 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,284 and has fallen 80.9% since, to $629 in 2021.
Across 232 payments — averaging $24.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$814
- Johnson & Johnson$675
- Amgen$527
- Rigel Pharmaceuticals, Inc.$500
- Astellas Pharma US Inc$331
- Genentech USA, Inc.$292
- plus $3K from 26 others
What the payments were for
- Food & beverage$5,04189%
- Education$61911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 40 | $814 |
| Johnson & Johnson | 19 | $675 |
| Amgen | 19 | $527 |
| Rigel Pharmaceuticals, Inc. | 5 | $500 |
| Astellas Pharma US Inc | 7 | $331 |
| Genentech USA, Inc. | 15 | $292 |
| Seagen Inc. | 15 | $266 |
| Pfizer | 27 | $253 |
| Pharmacosmos Therapeutics Inc. | 2 | $248 |
| E.r. Squibb & Sons, L.L.C. | 13 | $224 |
| Eisai Inc. | 5 | $202 |
| Incyte Corporation | 8 | $177 |
| Bristol Myers Squibb | 8 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $154 |
| Exelixis Inc. | 6 | $114 |
| Merck | 6 | $100 |
| Lilly USA, LLC | 5 | $91 |
| Novartis | 4 | $74 |
| Sanofi | 4 | $65 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Foundation Medicine, Inc. | 2 | $51 |
| Mylan Institutional Inc. | 2 | $43 |
| AMAG Pharmaceuticals, Inc. | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 2 | $32 |
| Gilead | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Dova Pharmaceuticals | 1 | $16 |
| Veracyte, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,660 in reported general payments places this provider in the 55th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Sunrise
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.